Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13540174 | 0.87 | PARP10 (0.62) | MAOBHRH3CHEK2MEN1CYP2D6 | |
| SCHEMBL12735909 | 0.80 | HPGD (0.54) | NFE2L2HRH3CHEK2MEN1CYP2D6 | |
| SCHEMBL7316232 | 0.79 | NFE2L2 (0.62) | NFE2L2MEN1KMT2AHPGDPARP15 | |
| SCHEMBL12735793 | 0.79 | CHEK2 (0.65) | HRH3CHEK2ITGB3ITGA2BPARP15 | |
| SCHEMBL8117489 | 0.78 | KMT2A (0.60) | MEN1CYP2D6KMT2AHRH2HRH1 | |
| SCHEMBL11893183 | 0.78 | NFE2L2 (0.60) | NFE2L2MEN1KMT2AHRH2HRH1 | |
| SCHEMBL7321013 | 0.78 | NFE2L2 (0.60) | NFE2L2HRH3MEN1KMT2AHPGD | |
| SCHEMBL12420657 | 0.78 | TP53 (0.57) | MEN1CYP2D6KMT2AHRH2HRH1 | |
| Hydrochloric Acid SCHEMBL31753574 | 0.77 | CHEK2 (0.64) | HRH3CHEK2ITGB3ITGA2BPARP15 | |
| SCHEMBL12420862 | 0.77 | NFE2L2 (0.63) | NFE2L2HRH3CHEK2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | NFE2L2 1770/4885MAOB 222/4885HRH3 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.